secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0000950170-22-003510
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics appoints former Biogen commercial lead Caren Deardorf to board
------------------------------------------------------------------------

- Caren Deardorf appointed as Class II director, initial term through 2023 annual meeting.
- She brings over 20 years at Biogen, led global commercial efforts for Spinraza in SMA.
- Board size increased from seven to eight members to accommodate the new appointment.
- Deardorf receives annual cash retainer of $40,000 plus $7,500 for committee service; granted 25,000 stock options vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/0000950170-22-003510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/crnx-20220311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer